Profusa (PFSA) Cash from Operations Growth (1y) (2023 - 2026)
Profusa (PFSA) Cash from Operations Growth (1y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.66 Bn | 175.36 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 128.55 Bn | 125.68 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 108.38 Bn | 99.16 Bn | 6.41 Bn | 1.78% |
| 4 | Boston Scientific | 68.11 Bn | 66.66 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 47.19 Bn | 43.52 Bn | 1.29 Bn | -84.38% |
| 6 | Dexcom | 28.54 Bn | 27.42 Bn | 750.30 Mn | 185.96% |
| 7 | GE HealthCare Technologies | 28.37 Bn | 26.09 Bn | 1.98 Bn | 16.00% |
| 8 | Smith & Nephew | 26.90 Bn | 26.33 Bn | - | - |
| 9 | Koninklijke Philips | 25.53 Bn | 22.40 Bn | 2.07 Bn | 122.43% |
| 10 | Profusa | 69,347.14 | -305,652.86 | - | -384.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -384.17% |
| Dec 31, 2025 | -2,055.04% |
| Sep 30, 2025 | -821.43% |
| Jun 30, 2025 | 108.96% |
| Mar 31, 2025 | -91.20% |
| Dec 31, 2024 | 31.06% |
| Sep 30, 2024 | -140.17% |
| Jun 30, 2024 | -44.50% |
| Mar 31, 2024 | 70.94% |
| Dec 31, 2023 | -92.48% |
| Sep 30, 2023 | -344.83% |
| Jun 30, 2023 | -329.44% |
| Mar 31, 2023 | -319.62% |